ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1341

Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users

Gisela Westhoff1, Rainer H. Straub2, Frank Buttgereit3, Johanna Callhoff4 and Angela Zink5, 1Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany, 2Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, 3Charité - Universitätsmedizin Berlin, Berlin, Germany, 4German Rheumatism Research Center, Berlin, Germany, 5German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Neuroendocrine Immune (NEI), patient outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: Data on the effects of oral contraceptives (OC) on the course of inflammatory arthritis (IA) are controversial. However, a recent analysis of data from the Norfolk Arthritis Register (NOAR) showed that the use of OC is associated with beneficial functional outcomes. We aimed at investigating the associations between OC use, need of therapies, and outcomes in women with early IA within the first year of care.

Methods: A total of 324 women with early IA (symptoms <6 months, 18 - 60 years, never having used hormone replacement therapy), were followed with respect to disease activity (CRP, ESR, S/TJC28, morning stiffness), use of DMARDs and glucocorticoids (GC) and patient-reported outcomes (PROs) according to the Rheumatoid Arthritis Impact of Disease Score (RAID 0-10), the PROFAD (0-10), the PHQ9 Depression Scale (0-27), and the Functional Scale FFbH (0-100). Use of OC was reported as never, past, or current. Outcomes by use of OC were adjusted for age, body mass index, number of natural children, and years of education using generalized linear models.

Results: At baseline, mean age was 46 ±10 years and symptoms lasted for 13 ±7 weeks. Of these women, 68% fulfilled the 2010 criteria for rheumatoid arthritis (RA), 82% were clinically diagnosed with RA at 12 months and 89% took DMARDs at that point in time. 24% had never used OC, 57% had used them in the past, and 19% used them currently. Current users were younger (36 vs. 50 yrs) and less frequently mothers than past and never users (58 vs. 80%). Independent of the time point (t0, 3, 6, 12 months), current use of OC, compared to past and never use, was not associated with biomedical measures, duration of morning stiffness or DMARD use (not shown). However, current and past OC use was associated with steadily decreasing GC use (54 and 57% at 12 months), while never users remained unaltered at 74% (P 0.016). Finally, current and past OC use was associated with significantly better outcomes in almost all considered patient-reported dimensions, such as pain, fatigue, well-being and function (Table). The effect of OC on PROs was, notably, almost the same in past and current users, although half of the past users were older than 50 years and might not have used OC for several years.

PROs at 12 months by use of oral contraceptives (means)

OC use

n

Pain*

Overall
fatigue

Problems getting started

Problems to
focus

Problems daily chores

Physical well being

Mental well being

Depression (PHQ9
0-27)

Physical function (0-100)

never

88

3.9

4.4

4.1

3.5

3.6

4.4

4.5

6.7

78.7

past

184

3.1

3.5

2.4

2.4

2.6

3.1

2.9

5.1

86.7

current

52

2.8

3.2

1.6

1.5

2.4

2.9

2.3

4.0

87.5

Total

324

3.3

3.7

2.5

2.3

2.8

3.3

3.1

5.2

85.1

P#

 

0.033

0.049

0.006

0.001

0.012

0.005

<0.001

0.021

0.018

*Means adjusted for age, BMI, number of children and education;#P never vs. current use

Conclusion: Our findings confirm that women with past or current OC use have better functional outcomes without having less signs of inflammation. The specific spectrum of obviously ameliorated conditions indicates that estrogens seem to have neuro- and psycho-protective effects on many symptoms that compromise well-being in IA. It may be suggested that OC act directly at CNS cytokines rather than influencing the course of peripheral inflammation. Long-lasting programming of CNS function may explain positive effects of OC. The use of hormones should be routinely reported in studies observing IA.


Disclosure:

G. Westhoff,
None;

R. H. Straub,
None;

F. Buttgereit,
None;

J. Callhoff,
None;

A. Zink,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/significantly-less-glucocorticoids-and-better-patient-reported-outcomes-in-women-with-early-inflammatory-arthritis-using-oral-contraceptives-compared-to-never-users/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.